News

Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced $40 million in Series A extension funding committed by Apple Tree Partners…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who…
Read More...

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and Nephron Pharmaceuticals, Inc. (Nephron), a leading manufacturer of sterile injectable drugs announced the…
Read More...

Landmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic…
Read More...

AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in…
Read More...

Aldeyra Therapeutics, Inc., a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, announced that it has entered…
Read More...

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the closing of a CHF25 million Series C financing led by Pureos…
Read More...

Prelude Therapeutics Incorporated and AbCellera announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for…
Read More...

Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology…
Read More...

I-Mab, a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel…
Read More...

Sosei Group Corporation will receive a US$3.75 million milestone payment under the 2019 multi-target Research Collaboration and License Agreement with Genentech, a member of the Roche…
Read More...

Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) to treat moderate to…
Read More...

GSK plc and Arrowhead Pharmaceuticals Inc. announced that they have reached an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to transfer…
Read More...

Kite, a Gilead Company and Epicrispr Biotechnologies announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene…
Read More...

Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, announced it has…
Read More...

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening…
Read More...

Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of macular edema…
Read More...

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review ImmunityBio’s resubmission of its Biologics License Application (BLA) for N-803, a…
Read More...

GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders announced that the National Medical Products…
Read More...

GSK plc announced positive preliminary results from its phase III trial evaluating the immune response and safety of Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults…
Read More...